DEF: Foghorn Therapeutics Sets 2026 Annual Meeting Date

Foghorn Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 24, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Summary

• Foghorn Therapeutics Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 24, 2026, at 9 a.m. Eastern Time.
• The meeting will be a virtual-only event, requiring registration at www.proxydocs.com/FHTX to attend and participate.
• Key proposals include the election of three Class III directors: Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall.
• Stockholders will also vote to ratify Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• An advisory vote will be held to approve the compensation of named executive officers and to determine the frequency of future advisory compensation votes (recommended as annually).
• The record date for determining stockholders entitled to vote is April 27, 2026.
• The company's Annual Report on Form 10-K for the year ended December 31, 2025, is available alongside the proxy materials.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it pertains to standard corporate governance and shareholder engagement, with no immediate negative financial news, but also no significant positive operational updates.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• Key leadership positions are up for election, providing an opportunity for shareholder oversight.
• The company is seeking ratification of its auditor, indicating a commitment to financial transparency.
• The company is providing advisory votes on executive compensation and its frequency, aligning with good corporate governance practices.

Risks

• The staggered board structure, with directors elected for three-year terms, may delay or prevent a change in management or control.
• The company has a policy prohibiting short sales, hedging, and pledging of company stock by directors, officers, and employees, which could limit their flexibility but also aligns interests with shareholders.

Future Outlook

The filing primarily concerns the upcoming annual meeting and does not contain specific forward-looking financial guidance. However, it outlines proposals for director elections, auditor ratification, and executive compensation votes, which are standard governance procedures.

Management Comments

• "Your vote is important. Whether or not you expect to attend the virtual-only Annual Meeting, we urge you to vote your shares..."
• "Thank you for your ongoing support of and interest in Foghorn Therapeutics Inc."
• "The Board of Directors unanimously recommends that you vote FOR the nominees for Class III Directors."
• "The Board of Directors unanimously recommends that you vote FOR the ratification of the selection of Deloitte & Touche LLP..."
• "The Board of Directors unanimously recommends that you vote FOR the advisory vote approving the compensation of the Named Executive Officers."
• "The Board of Directors unanimously recommends that you vote for a frequency of 1 YEAR for future advisory votes to approve the compensation of our Named Executive Officers."

Industry Context

StockSavvy.ai notes that this DEF 14A filing from Foghorn Therapeutics Inc. is typical for a publicly traded biotechnology company preparing for its annual shareholder meeting. The proposals align with standard corporate governance practices, including director elections, auditor ratification, and advisory votes on executive compensation, reflecting industry norms for transparency and accountability.

Corporate Governance

Related Party Transactions

• Consulting Agreement with Cigall Kadoch, Ph.D. (academic co-founder, former director, >5% shareholder) for advisory services related to chromatin remodeling. Paid $0.2 million in 2025 and 2024.
• Strategic collaboration with Eli Lilly and Company (Lilly), a >5% shareholder, including cost-sharing for the SMARCA2 Selective inhibitor program. Foghorn paid Lilly $8.2 million in 2025.
• The 2026 Equity Offering involved significant investors who are also >5% shareholders: entities affiliated with BVF Partners, L.P., Flagship Pioneering, Inc., Deerfield Partners LP, and FMR LLC.

Stakeholder Impact

• Shareholders: Will vote on director elections, auditor ratification, and executive compensation, influencing corporate governance and executive pay.
• Management: Subject to shareholder votes on compensation and director oversight.
• Employees: Benefit from 401(k) matching contributions and are subject to the insider trading policy.
• Auditors (Deloitte & Touche LLP): Seek ratification for the fiscal year ending December 31, 2026.
• Investors (including >5% shareholders): Participate in the 2026 equity offering and have ongoing governance rights.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 24, 2026.
• Conduct advisory votes on executive compensation and its frequency.
• Elect directors for three-year terms.
• Ratify the selection of the independent registered public accounting firm.
• Consider stockholder proposals for future meetings according to specified deadlines.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates that would warrant a buy or sell recommendation. It outlines standard governance procedures and upcoming votes. Therefore, a 'hold' recommendation is appropriate, pending future operational or financial disclosures.

Keywords

Foghorn Therapeutics, DEF 14A, Proxy Statement, Annual Meeting, Stockholders Meeting, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, SEC Filing